CA2544480A1 — Novel 8-(piperazine-1-yl)- and 8-([1,4]diazepan-1-yl)-xanthine, the production and use thereof in the from of a drug
Assigned to Boehringer Ingelheim International GmbH · Expires 2005-06-09 · 21y expired
What this patent protects
The invention relates to a substituted XANTHINE of formula (I), wherein R1 to R3 and n are such as defined in claims from 1 to 8 and tautomers, enantiomers, diastereomers, mixtures, prodrugs and the salts thereof, said substances exhibiting valuable pharmacological properties, in…
USPTO Abstract
The invention relates to a substituted XANTHINE of formula (I), wherein R1 to R3 and n are such as defined in claims from 1 to 8 and tautomers, enantiomers, diastereomers, mixtures, prodrugs and the salts thereof, said substances exhibiting valuable pharmacological properties, in particular an inhibition on the activity of dipeptidylpeptidasa-IV enzyme (DPP-IV).
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.